Skip to main content

Advertisement

Table 4 Renal function recovery after the 1st date of renal function decline among patients with renal function deterioration (n = 760)

From: Impact of urate-lowering drugs on the progression and recovery from chronic kidney disease among gout patients

  Person-days of follow-up Number of patients Events of CKD recovery Incidence rate (95% CI) per 1000 person-days Hazard ratio (95% CI)
Entire cohort 158,861 741 571 3.59 (3.30–3.89)
Type of ULD
 Allopurinol 19,509 39 26 1.33 (0.82–1.84) Reference
 Febuxostat 19,639 156 122 6.21 (5.11–7.31) 2.17 (1.40–3.47)*
 Uricosuric agents 119,713 546 423 3.53 (3.20–3.87) 1.80 (1.20–2.83)*
eGFR 60–89
 Allopurinol 3896 11 9 2.31 (1.06–4.39) Reference
 Febuxostat 5390 24 19 3.53 (1.94–5.11) 0.88 (0.39–2.13)
 Uricosuric agents 54,434 202 148 2.72 (2.28–3.16) 0.87 (0.44–1.91)
eGFR 30–59
 Allopurinol 5615 12 8 1.42 (0.62–2.81) Reference
 Febuxostat 2866 26 21 7.33 (4.19–10.46) 2.69 (1.18–6.71)*
 Uricosuric agents 46,123 216 167 3.62 (3.07–4.17) 2.18 (1.10–4.99)*
eGFR 15–29
 Allopurinol 7004 14 9 1.28 (0.59–2.44) Reference
 Febuxostat 7913 76 62 7.84 (5.88–9.79) 2.29 (1.03–5.65)*
 Uricosuric agents 16,598 103 87 5.24 (4.14–6.34) 1.98 (0.91–4.75)
eGFR < 15
 Allopurinol 2994 2 0 – – Reference
 Febuxostat 3470 30 20 5.76 (3.24–8.29)
 Uricosuric agents 2558 25 21 8.21 (4.70–11.72)
  1. The eGFR groups were based on the value of the first date of renal function decline, and the outcome was an improvement in renal function to more than one eGFR group
  2. * p < 0.05